As a part of my M.Sc. Nursing course, I have prepared PPT on Bengin Prostate Hyperplasia, which is an important topic from clinical as well as exam point of view. I hope this material will be helpful to the prospect nursing student. However, refer books for the better understanding of the topic.
Urinary Tract Fistulas -(VVF) Etiology, Diagnosis, ManagementVikas V
Urinary Tract Fistulas - Etiology, Diagnosis, Management
Surgical and Relevant Anatomy, Classification, eitiology, VVF in Detail, Examination and Diagnosis, Management of VVF - Both Conservative And Surgical Management - Steps of Surgical Management, Post operative Management.
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control.
The urethra's main job in males and females is to pass urine outside the body. This thin tube also has an important role in ejaculation for men. When a scar from swelling, injury or infection blocks or slows the flow of urine in this tube, it is called a urethral stricture. Some people feel pain with a urethral stricture.
Urinary Tract Fistulas -(VVF) Etiology, Diagnosis, ManagementVikas V
Urinary Tract Fistulas - Etiology, Diagnosis, Management
Surgical and Relevant Anatomy, Classification, eitiology, VVF in Detail, Examination and Diagnosis, Management of VVF - Both Conservative And Surgical Management - Steps of Surgical Management, Post operative Management.
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control.
The urethra's main job in males and females is to pass urine outside the body. This thin tube also has an important role in ejaculation for men. When a scar from swelling, injury or infection blocks or slows the flow of urine in this tube, it is called a urethral stricture. Some people feel pain with a urethral stricture.
A benign (not cancer) condition in which an overgrowth of prostate tissue pushes against the urethra and the bladder, blocking the flow of urine. Also called benign prostatic hyperplasia and BPH.
Decreased caliber and force of the stream
Problems starting(hesitancy) and stopping urine stream; post-void dribbling
Impaired bladder emptying
- high risk of infection and hydronephrosis
Urinary retention
Incontinence
Nocturia; polyuria / Dysuria
Hypertrophy of bladder wall muscle
- increased risk for bladder diverticula
Microscopic hematuria maybe present
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. Introduction
– Histologic evidence of prostrate enlargement begins about the third decade of life
and increases proportionally with aging.
– Specifically, about 43% of men in their 40s
– 50% of men in their 50s,
– 75% to 88% in their 80s, and
3. – Nearly 100% of men reaching the ninth decade of life.
– European and African Americans have similar prevalence rates of BPH,
– but Asian Americans tend to have lower rates of BPH.
– The incidence of BPH is lowest among immigrants, however, and it increases
with subsequent generations, suggesting environmental as well as possible racial
differences.
4. Definition
The prostrate is the genital organ most commonly affected by benign and
malignant neoplasms.
Benign enlargement of the prostate gland is an extremely common process
that occurs in nearly all men with functioning testes.
5. -The term benign prostatic hyperplasia or hypertrophy (BPH) is used to describe
the disorder that occurs when the prostate growth sufficiently obstructs the urethral
outlet resulting in bothersome
lower urinary tract symptoms (LUTS), urinary tract infection (UTI),
hematuria, or compromised upper urinary tract function.
6. It is defined as
– “Noncancerous increase in size of prostate gland which involves
hyperplasia in Prostatic stromal and epithelial cell
– resulting in formation of large, fairly discrete nodules, in
transitional zone of prostate,
– Which push on and narrow the urethra resulting in an increase
resistance to flow of urine from the bladder.”
7.
8. ETIOLOGY AND RISK FACTORS
– It is arrested following bilateral orchiectomy.
– Androgens, and particularly testosterone, are not direct causes of
BPH, their presence is critical to the normal growth and
development of the prostate as well as BPH
– Within the prostate, testosterone is converted to
dihyrotestosterone (DHT) under the influence of an enzyme called
5-alpha reductase.
9. – DHT is active form of testosterone that supports prostate growth
and development throughout life, and the prostate remains
sensitive to androgen production throughout life to maintain both
prostate size and function.
10. Additional factors associated
– Defect in local substances that regulate the programmed cellular death
(apoptosis)
– Imbalances of local growth factors,
– Local inflammation, and
– Genetic factor
– Frequent use of alpha-adrenergic agonists commonly found in over-the-
counter cold medications or diet pills increases the severity of
bothersome LUTS
11. Multiple possible risk factors for
BPH
– Dietary factors have been examined, and lycopene in cooked tomatoes,
green and yellow vegetables, and other elements of a traditional
Japanese diet appear to provide some protection against BPH
– Smoking has been hypothesized to exert a protective effect on BPH
because it reduces serum testosterone levels
– Heavy alcohol use and cirrhosis of the liver impede prostate
enlargement.
12. Obesity
– Particularly an increased abdominal girth may increase the risk for BPH,
– diabetes mellitus appears to exert only a modest affect on the incidence
of BPH or its severity.
15. Complications of benign prostate
enlargement.
– Compromised renal function or renal failure.
– Urinary tract infection and hematuria also may be associated with
BPH
– Urinary retention and obstruction
16. – International Prostate Symptom Score Index (IPSS)
– is a short questionnaire commonly used by urologists to
assess the client´s opinion about the severity of these
manifestations
– This instrument provides a reliable and valid description
of bothersome LUTS associated with BPH,
– but it fails to differentiate LUTS caused by BPH from
those caused by other, non-obstructive etiologies.
17. – A DIGITAL RECTAL EXAMINATION (DRE) is performed to
assess prostate size and to differentiate BPH from
prostate enlargement
– BPH reveals a symmetrically enlarged prostate with an
obliterated central sulcus.
– Prostatic infection (prostatitis) is associated with
symmetric enlargement, a boggy consistency, and
discomfort on palpation.
– Adenocarcinoma of the prostate is associated with
asymmetric enlargement, hardened nodules, or
induration
18. – Urinalysis and blood tests for kidney function (urea nitrogen or
blood urea nitrogen (BUN) and Creatinine)
– Urine culture or prostate-specific antigen (PSA) to assess for
cancer
– Chemistry panels, such as electrolyte, liver function, and blood
coagulation studies, may be added if surgery is being considered.
19. – Uroflowmetry may be completed to assess the voiding pattern
and measure maximum and average flow rates.
– A man starts this test with a full bladder, voids into a specific
toilet or container, and empties his bladder to the best of his
ability.
– Residual urine is determined after the urine flow either by
catheterization or by ultrasonography
– A maximum urinary flow of 12 ml/sec or greater in a man
aged 55 years or older greatly reduces the likelihood of
urethral obstruction associated with BPH
20. MEDICAL MANAGEMENT
Alpha blockers:
– These medications relax bladder neck muscles and muscle fibers
in the prostate, making urination easier.
– Alpha blockers — which include alfuzosin (Uroxatral), doxazosin
(Cardura), tamsulosin (Flomax), and silodosin (Rapaflo) — usually
work quickly in men with relatively small prostates.
21. 5-alpha reductase inhibitors:
– These medications shrink prostate by preventing hormonal
changes that cause prostate growth. These medications — which
include finasteride (Proscar) and dutasteride (Avodart) — might
take up to six months to be effective.
22. Combination drug therapy
– Doctor might recommend taking an alpha blocker and a 5-alpha
reductase inhibitor at the same time if either medication alone
isn't effective.
– Tadalafil (Cialis). Studies suggest this medication, which is often
used to treat erectile dysfunction, can also treat prostate
enlargement
23. PHYTOTHERAPEUTIC
AGENTS
– Use of herbs for healing purposes to manage BPH.
– The most widely used agent is Serenoa repens (saw palmetto).
– Saw palmetto is derived from a dwarf palm tree that grows in the
southwest United States;
– It contains a mixture of fatty acids, sterols (alcohol-based steroid),
and flavonoids.
– Its principal action in relationship to BPH appears to be inhibition
of 5-alpha reductase enzyme activities similar to the action
27. SURGICAL MANAGEMENT
INVASIVE SUGERIES
PROSTATECTOMY :
The part of the gland causing the obstruction is removed in a
procedure called a prostatectomy.
1. Transurethral Resection Of The Prostate
2. Suprapubic Prostatectomy:
3. Retropubic Prostatectomy:
4. Perineal Prostatectomy:
28.
29. OPERATIVE
TECHNIQUE
TRANSURETHRAL RESECTION OF THE PROSTATE
widely used technique for managing BPH, and it continues
to be the ``gold standard`` against which all other
procedures are measured
Resectoscope is inserted through the urethra
The surgeon visualizes the inside of the bladder by inserting
a cystoscope (telescopic lens) through the resectoscope.
30. SUPRAPUBIC
PROSTATECTO
MY:– Suprapubic prostatectomy is a surgical approach
that involves a lower abdominal incision
– Prostate is too large
– A bladder abnormality needs correction
– An abnormal surgical exploration is necessary
31. RETROPUBIC
PROSTATECTOMY:
– The surgeon approaches the prostate through a low abdominal
incision without entry into the bladder.
– This is the operation of choice when the prostate is very large and
a severe urethral stricture is present.
32. PERINEAL
PROSTATECTOMY:An incision is made into the perineum
between the anus and the scrotum.
This operation is rarely used for treating BPH
because of the great potential for erectile
dysfunction.
33. MINIMALLY INVASIVE
THERAPIES:
1. LASER-ASSISTED PROCEDURES:
2. Prostatic Stent
3. Hyperthermia And Thermal Therapy
4. Transurethral Electrovaporization
Transurethral Incision Of The Prostate
34. LASER-ASSISTED PROCEDURES:
– Transurethral ultrasound-guided laser incision of the prostate
(TULIP) is a minimally invasive procedure in which a laser is used to
make the incision into the prostate
35. Laser ablation of prostatic tissue
– Its use subsequently declined because of the need for prolonged
catheterization following the procedure and the length of time
required to resect enough prostatic tissue to effectively relieve
bladder outlet obstruction.
36. Holmium laser enucleation of the prostate (HoLEP)
and photoselective vaporization of the prostate (
Green Light Laser)
37.
38. HYPERTHERMIA AND THERMAL
THERAPY:
– Hyperthermia refers to the administration of temperature below
45’C; thermal therapy
– Three techniques- microwaves, radiofrequency, or high-intensity
ultrasound waves-may be used to heat the prostate and destroy
prostate tissue
– Temperature probe is placed in the rectum, and water is circulated
through the system to prevent urethral or rectal heat injury
39. The transurethral needle
ablation (TUNA) system
– Uses radiofrequency energy to destroy prostatic tissue.
– Special needles are placed into the prostate, and radiofrequency
energy is used to provoke tissue coagulation and necrosis.
40. PROSTATIC STENT:
– Prostatic stent insertion is indicated for clients who are extremely
poor operative risks.
– The mesh-like tube ( a coil-shaped device has also been used) can
be inserted through a endoscope into the prostatic urethra, where
it holds the urethra open mechanically.
– Over time, usually about 3-6 months, epithelial cells grow over the
stent, which is permanent in most cases
42. Risk for injury related to presence of urinary
catheters, hematuria, irrigation, or
suprapubic drains
INTERVENTION
– Maintain irrigation.
– Monitor For Bleeding:
– PREVENT CATHETER DISLODGEMENT:
– Monitor For Retention:
43. Acute pain related to surgery and
bladder spasms.
– Ensure that the drainage system is not blocked
– Antispasmodic medications, such as belladonna and opium (B&O)
suppositories, propantheline bromide (Pro-Banthine)